Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases
| Autor: | B Hepperle, Sc Tang, John Hanson, Lydia Visser, Sibrand Poppema |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male Cancer Research Pathology medicine.medical_specialty Adolescent Follicular lymphoma Gene Expression Biology Polymerase Chain Reaction Immunoglobulin kappa-Chains Immunoglobulin lambda-Chains Proto-Oncogene Proteins Gene expression medicine Humans Aged Retrospective Studies Aged 80 and over Gene Rearrangement Large cell Breakpoint Large-cell lymphoma Gene rearrangement Middle Aged medicine.disease Molecular biology Immunohistochemistry Non-Hodgkin's lymphoma Lymphoma Oncology Proto-Oncogene Proteins c-bcl-2 Female Immunoglobulin Light Chains Lymphoma Large B-Cell Diffuse |
| Zdroj: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 12(1) |
| ISSN: | 0732-183X |
| Popis: | PURPOSE The goal of this study was to assess the prognostic significance of a rearrangement of the major breakpoint region of the bcl-2 gene and/or expression of bcl-2 protein in diffuse large-cell lymphomas of B-cell origin. PATIENTS AND METHODS All 83 patients diagnosed at the Cross Cancer Institute between 1987 and 1992 with malignant lymphoma (ML), diffuse large-cell ML non-cleaved-cell ML or cleaved-cell ML, or with diffuse large-cell immunoblastic ML were studied. bcl-2 rearrangement was identified by a polymerase chain reaction technique. This technique detects the approximately 60% of rearrangements involving the major breakpoint region bcl-2 gene (bcl-2-MBR). bcl-2 protein expression was studied by immunohistochemistry. RESULTS More than 66% of the cases expressed bcl-2 protein, whereas 18% had a detectable bcl-2-MBR gene rearrangement. Overall, cases with bcl-2-MBR rearrangement had shorter disease-free periods. Cases with nodal and extranodal presentation had a similar frequencies of bcl-2-MBR rearrangement; however, the disease-free period of patients with extranodal presentation and bcl-2-MBR rearrangement was significantly shorter than that of those without rearrangement. CONCLUSION bcl-2 protein is frequently expressed in diffuse large-cell lymphomas, but does not influence prognosis. The bcl-2-MBR gene rearrangement may possibly be associated with a shorter disease-free period, particularly in the specific setting of a lymphoma with extranodal presentation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|